Fundamental Analysis of MAINZ BIOMED NV(NASDAQ:MYNZ) stock

Fundamental Rating

Taking everything into account, MYNZ scores 2 out of 10 in our fundamental rating. MYNZ was compared to 565 industry peers in the Biotechnology industry. MYNZ may be in some trouble as it scores bad on both profitability and health. MYNZ is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MYNZ has reported negative net income.

MYNZ had a negative operating cash flow in the past year.

MYNZ had negative earnings in each of the past 5 years.

MYNZ had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MYNZ has a Return On Assets of -311.04%. This is amonst the worse of the industry: MYNZ underperforms 95.01% of its industry peers.

		Industry Rank	Sector Rank
ROA	-311.04%
ROE	N/A
ROIC	N/A

ROA(3y)-139.16%

ROA(5y)-127.77%

ROE(3y)-393.42%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 56.91%, MYNZ is doing good in the industry, outperforming 78.97% of the companies in the same industry.

MYNZ's Gross Margin has improved in the last couple of years.

MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	56.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y32.46%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.

MYNZ has more shares outstanding than it did 1 year ago.

The debt/assets ratio for MYNZ is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -20.75, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.

MYNZ has a worse Altman-Z score (-20.75) than 85.74% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-20.75

ROIC/WACCN/A

WACC5.87%

2.3 Liquidity

A Current Ratio of 0.24 indicates that MYNZ may have some problems paying its short term obligations.

With a Current ratio value of 0.24, MYNZ is not doing good in the industry: 96.61% of the companies in the same industry are doing better.

MYNZ has a Quick Ratio of 0.24. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.19, MYNZ is not doing good in the industry: 96.97% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.24
Quick Ratio	0.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MYNZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.96%, which is quite good.

Looking at the last year, MYNZ shows a very strong growth in Revenue. The Revenue has grown by 68.96%.

MYNZ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.26% yearly.

EPS 1Y (TTM)12.96%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.32%

Revenue 1Y (TTM)68.96%

Revenue growth 3Y22.26%

Revenue growth 5YN/A

Sales Q2Q%109.99%

3.2 Future

MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.58% yearly.

MYNZ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 156.06% yearly.

EPS Next Y45.58%

EPS Next 2Y24.09%

EPS Next 3Y16.86%

EPS Next 5Y14.58%

Revenue Next Year27.57%

Revenue Next 2Y56.37%

Revenue Next 3Y113.85%

Revenue Next 5Y156.07%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MYNZ's earnings are expected to grow with 16.86% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.09%

EPS Next 3Y16.86%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MYNZ does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MAINZ BIOMED NV

NASDAQ:MYNZ (11/20/2024, 8:00:01 PM)

Premarket: 0.224 0 (0%)

0.224

+0 (+2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.90M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-311.04%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	56.91%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.24
Quick Ratio	0.19
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)12.96%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y45.58%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)68.96%

Revenue growth 3Y22.26%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MAINZ BIOMED NV (MYNZ)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens